Presentation

BioArctic AB (publ) is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of diseases that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. BioArctic’s main research areas are Alzheimer’s disease and Parkinson’s disease where there are large unmet medical needs. Its programs include BAN2401, an amyloid beta antibody, which is partnered with Eisai and is in a Phase 3 clinical trial for early Alzheimer's disease. For Alzheimer’s disease, the company also develops four other fully-owned preclinical stage antibodies. In the Parkinson’s Disease area, BioArctic has a partnership with Abbvie to develop ABBV-0805 and other anti-alpha synuclein antibodies. A Phase 1 clinical study with ABBV-0805 is ongoing. BioArctic also has other research stage projects with potential broad application in neurodegeneration. In addition, BioArctic is developing a blood brain barrier transport technology platform and imaging and biochemical biomarkers for Alzheimer’s and Parkinson’s diseases in various collaborations. BioArctic AB (publ) was founded in 1992 and is headquartered in Stockholm, Sweden.